News Sentiment

AMLX sentiment intelligence

Amylyx Pharmaceuticals Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 52 Balanced news tone 53 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Drug Manufacturers - Specialty & Generic Read-through group
Latest close 17.77 Week of 10 Jul 2026
Weighted tone 52/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

82/100 classification confidence.

Company focus 53

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

-2.7% over one week, +21.8% over four weeks, trend active, and materially above fair value.

Latest direct headline Negative

Trade Alert: Chief Legal Officer & General Counsel Of Amylyx Pharmaceuticals Gina Mazzariello Has Sold Stock

Market Reaction

Balanced read

61/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 82/100 classification
One-week reaction -2.7% Price reacting lower
Trend fit Trend active 21.8% over four weeks
Fair value 81.5% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 11
Neutral 35
Negative 7

Relevance

Why the article matched

Direct first
Direct company coverage 53
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 6
TradingView 6
simplywall.st 5
Market source 5
Quartr 3
Finviz 3
Moomoo 3
www.marketscreener.com 3

Event Lens

What the news is about

Classified themes
Market update 33
Earnings 7
Analyst action 5
Regulatory and legal 3
Balance sheet 2
Deals and strategy 1
Guidance 1
Capital return 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-53 of 53
Investing.com Direct company coverage

Amylyx Pharmaceuticals stock hits 52-week high at $18.65

Amylyx Pharmaceuticals Inc. (AMLX) stock has reached a 52-week high of $18.65, though InvestingPro analysis suggests it is overvalued. The company has shown significant gains over the past year, with a 171.57% return, and continues to advance its drug candidates despite a recent

Tone
Positive 74/100
Event
Market update
Published
25 Jun 2026 15:40
Source
Investing.com